TABLE 2.
Impact of overexpression of cmrA and PA2048
| Transformant | Value without (with) arabinose fora: |
|||||
|---|---|---|---|---|---|---|
| Transcript levelb |
MIC (μg ml−1)c |
|||||
| cmrA | PA2048 | mexE | CIP | CHL | TMP | |
| PA14(pJN105) | 1 (1) | 1 (1) | 1 (1) | 0.125 (0.125) | 128 (128) | 128 (128) |
| PA14(pJN105::cmrAPA14) | 385 (>1,000) | 4.5 (3.8) | 1.1 (1.3) | 0.125 (0.125) | 128 (128) | 128 (128) |
| PA14(pJN105::cmrAPJ01) | 458 (>1,000) | 35 (53) | 20 (50) | 1 (1) | 1,024 (2,048) | 256 (512) |
| PA14(pJN105::PA2048) | 1.6 (4.1) | 135 (>1,000) | 52 (270) | 1 (2) | 1,024 (2,048) | 256 (512) |
a
Values obtained without and with 0.5% arabinose, used as an inducer of gene expression.
b
Expressed as the ratio to the value for PA14(pJN105).
c
CIP, ciprofloxacin; CHL, chloramphenicol; TMP, trimethoprim.